OSR HEALTH, INC. Research and Development Expense
OSR HEALTH, INC. (OSRH) reported Research and Development Expense of $207.78 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- OSR HEALTH, INC. research and development expense for the quarter ending 2026-06-30 was $94.63K, a 76.79% increase year-over-year.
- OSR HEALTH, INC. research and development expense for the quarter ending 2026-03-31 was $113.15K, a 25.51% increase year-over-year.
- OSR HEALTH, INC. research and development expense for the quarter ending 2025-12-31 was $176.57K, a 1119.72% increase year-over-year.
- OSR HEALTH, INC. research and development expense for the quarter ending 2025-09-30 was -$1.79K, a 103.28% decline year-over-year.
- OSR HEALTH, INC. research and development expense for fiscal 2025 was $318.45K, a 97.60% increase from fiscal 2024.
- OSR HEALTH, INC. research and development expense for fiscal 2024 was $161.16K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $94.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $207.78K 10-Q · filed 2026-08-14 | $384.34K derived: sum of 3 quarters · filed 2026-08-14 | $382.55K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $113.15K 10-Q · filed 2026-05-13 | $289.72K derived: sum of 2 quarters · filed 2026-05-13 | $287.92K derived: sum of 3 quarters · filed 2026-05-13 | $341.45K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $176.57K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $174.77K derived: sum of 2 quarters · filed 2026-03-31 | $228.30K derived: sum of 3 quarters · filed 2026-08-14 | $318.45K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$1.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $51.73K derived: sum of 2 quarters · filed 2026-08-14 | $141.88K 10-Q · filed 2025-11-12 | $156.36K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $53.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $143.67K 10-Q · filed 2026-08-14 | $158.15K derived: sum of 3 quarters · filed 2026-08-14 | $212.85K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $90.15K 10-Q · filed 2026-05-13 | $104.63K derived: sum of 2 quarters · filed 2026-05-13 | $159.33K derived: sum of 3 quarters · filed 2026-05-13 | $204.59K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $14.48K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $69.18K derived: sum of 2 quarters · filed 2026-03-31 | $114.44K derived: sum of 3 quarters · filed 2026-03-31 | $161.16K 10-K · filed 2026-03-31 |
| 2024-09-30 | $54.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $99.96K derived: sum of 2 quarters · filed 2025-11-12 | $146.68K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $45.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $91.97K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $46.72K 10-Q · filed 2025-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |